Table 1.
|
Women |
Men |
Test for group difference |
Significance |
Effect size |
||
---|---|---|---|---|---|---|---|
Variable | n | M (SD) | n | M (SD) | F | p | η2 |
Patient age |
535 |
50.7 (10.9) |
122 |
61.1 (14.3) |
79.01 |
<0.001 |
0.108 |
Years since first diagnosis |
533 |
4.9 (5.3) |
122 |
5.3 (5.4) |
0.53 |
0.468 |
0.001 |
Length of current relationship |
515 |
19.8 (13.7) |
118 |
25.7 (16.8) |
16.55 |
<0.001 |
0.026 |
|
n |
% |
n |
% |
χ2 |
p |
φ |
Ethnicity: |
|
|
|
|
0.51 |
0.774 |
0.028 |
Aust/White European |
508 |
95.7 |
114 |
94.2 |
|
|
|
Asian |
14 |
2.6 |
4 |
3.3 |
|||
Other |
9 |
1.7 |
3 |
2.5 |
|||
Cancer type: |
|
|
|
|
519.19 |
<0.001 |
0.364 |
Breast |
425 |
80 |
- |
- |
|
|
|
Gynecologic |
45 |
8.5 |
- |
- |
|||
Prostate |
- |
- |
87 |
72.5 |
|||
Genitourinary (other) |
4 |
0.8 |
7 |
5.8 |
|||
Hematological/Blood |
23 |
4.3 |
14 |
11.7 |
|||
Digestive/Gastrointestinal |
11 |
2.1 |
4 |
3.3 |
|||
Neurologic |
6 |
1.1 |
4 |
3.3 |
|||
Skin |
8 |
1.5 |
2 |
1.7 |
|||
Othera |
9 |
1.7 |
2 |
1.7 |
|||
Cancer classification: |
|
|
|
|
10.52 |
.001 |
0.127 |
Sexual cancer type |
474 |
89.3 |
94 |
78.3 |
|
|
|
Non-sexual cancer type |
57 |
10.7 |
26 |
21.7 |
|||
Stage of disease: |
|
|
|
|
27.19 |
<0.001 |
0.188 |
No longer detectable/In remission |
430 |
80.8 |
71 |
58.7 |
|
|
|
Receiving treatment |
16 |
3.0 |
7 |
5.8 |
|||
Otherb |
86 |
16.2 |
43 |
35.5 |
|||
Relationship status: |
|
|
|
|
3.12 |
0.374 |
0.032 |
Partnered – Living together |
414 |
77.4 |
96 |
78.7 |
|
|
|
Partnered – Not living together |
34 |
6.4 |
10 |
8.2 |
|||
Not in a relationship |
76 |
14.2 |
16 |
13.1 |
|||
Other/Not specified |
11 |
2.1 |
- |
- |
|||
Sexual identity: |
|
|
|
|
405.16 |
<0.001 |
0.858 |
Heterosexual |
434 |
96.7 |
92 |
91.1 |
|
|
|
Non heterosexual |
15 |
3.3 |
9 |
8.9 |
|||
Current sexual relationship: |
|
|
|
|
0.99 |
0.319 |
0.039 |
Yes |
404 |
76.2 |
87 |
71.9 |
|
|
|
No | 126 | 23.8 | 34 | 18.6 |
Note a“Other” includes: Respiratory/Thoracic, Head & Neck, various, each less than 1%; b “Other” includes: a new different cancer; active monitoring; outcome not specified.